Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 2 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
The Sponsor  and Investigator s have approved this protocol version, and I confirm hereby [CONTACT_548067] s tudy according 
to the protocol and per  applicable principles of the World Medical Association Declaration of Helsinki  and Good Clinical 
Practice (GCP) guidelines as per  ISO [ZIP_CODE], any conditions of approval imposed by [CONTACT_548068] ( EC) or 
governing regulatory body, and applicable  local and federal laws and regulations. The investigator should not deviate 
from this protocol except for emergency use. I have read and understood and agree to abide by [CONTACT_548069].  
Local Principal Investigator [INVESTIGATOR_73672]: 
 
Investigator Signature   [CONTACT_73714], Department, Address  
 
 
 
Local Co-Investigator at study site: 
 
Co-Investigator Signature   [CONTACT_73714], Department, Address  
 
  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 3 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
Table of Contents  
Document and Version Control  ........................................................................... [ADDRESS_717400] of Abbreviations and Terms  .......................................................................... 7  
Synopsis  ............................................................................................................. 8  
1. Background and Justification  ..................................................................... 15 
2. Device/Product Description  ....................................................................... 15 
2.1 Identity, Mechanism, and Function  ............................................................................. 15 
2.2 Intended Use  ................................................................................................................ 15 
2.3 Packaging and Labeling  ................................................................................................ 16 
2.4 Concomitant/Ancillary Administrations  ...................................................................... 16 
2.4.1  Medications and Biologic Products  ............................................................................. 16 
2.4.2  Laboratory Tests and Sample Processing  .................................................................... 16 
2.5 Accountability  .............................................................................................................. 16 
2.5.1  Issuance  ....................................................................................................................... 16 
2.5.2  Disposition  ................................................................................................................... 16 
2.6 Anticipated Risks and Benefits  .................................................................................... 17 
2.6.1  Risk Category and Rationale  ........................................................................................ 17 
2.6.2  Device/Product Classification and Rationale  ............................................................... 17 
3 Objectives and Endpoints  .......................................................................... 18 
3.1 Purpose of the Study  ................................................................................................... 18 
3.1.1  Primary Objective  ........................................................................................................ 18 
3.1.2  Safety Objective(s):  ...................................................................................................... 18 
3.1.3  Study Endpoints  ........................................................................................................... 18 
4 Study Design .............................................................................................. 18 
4.1 Summary of Study Design  ............................................................................................ 18 
4.2 Study Population  .......................................................................................................... 19 
4.3 Number of Participants  ................................................................................................ 19 
4.4 Eligibility Criteria  .......................................................................................................... 19 
4.5 Recruiting and Screening  ............................................................................................. 21 
4.6 Skin Tone Diversity  ...................................................................................................... 21 
4.7 Criteria for Withdrawal/Discontinuation ..................................................................... 22 
5 Study Procedures  ...................................................................................... 23 
5.1 Procedure General Information  .................................................................................. 23 
5.2 Desaturation Study Gas Delivery System  .................................................................... 23 
5.3 Participant Preparation  ............................................................................................... 24 
5.4 Description of Study Procedures  ................................................................................. 24 
5.5 Follow -up ..................................................................................................................... 26 
6 Study Data Collection and Assessments  ..................................................... 27 
6.1 Primary Assessment ..................................................................................................... 27 
6.2 Safety Assessments  ...................................................................................................... 27 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 4 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
7 QUALIFICATION AND TRAINING PLAN  ....................................................... 27 
7.1 Staff Qualifications  ....................................................................................................... 27 
7.2 Training Plan for the Protocol and Research Device/Product  ..................................... 28 
8 Safety  ........................................................................................................ 28 
8.1 Anticipated Adverse Events  ......................................................................................... 28 
8.2 Safety/Anticipated AE Risks  ......................................................................................... 28 
8.3 Adverse Event Definitions ............................................................................................ 29 
8.4 Documentation of Adverse Events  .............................................................................. 30 
8.5 Reporting of Safety Events  .......................................................................................... 32 
8.6 Reporting of Device Deficiencies/Complaints  ............................................................. [ADDRESS_717401] of the Study  ...................................................................... 32 
9.1 Ethics Committee  ......................................................................................................... 32 
9.2 Regulatory Agencies and Competent Authority(ies)  ................................................... 33 
9.3 Management of Protocol Modifications and Amendments  ........................................ 33 
9.4 Management of Protocol Deviations  ........................................................................... 33 
9.5 Participant Information and Informed Consent  .......................................................... 33 
9.6 Suspension/Early Termination of the Study  ................................................................ 34 
10 Statistical Methods  .................................................................................... 34 
10.1  Statistical Hypothesis  ................................................................................................... 34 
10.2  Sample Size Determination  ......................................................................................... 34 
10.3  Statistical Analysis  ........................................................................................................ 34 
10.3.1 General Statistical Methods  ...................................................................................... 34 
10.3.2 Analysis of Primary Endpoint(s)  ................................................................................. 35 
10.3.3  Safety Analysis  ........................................................................................................... 35 
10.4  Handling of Missing Data  ............................................................................................. 35 
10.5  Deviation(s) from the Original Statistical Plan ............................................................. 35 
11 Quality Assurance and Control  .................................................................. 35 
11.1  Data Management  ....................................................................................................... 35 
11.2  Completion of Case Report Forms (CRFs)  .................................................................... [ADDRESS_717402] Keepi[INVESTIGATOR_007]  ............................................................................. 35 
11.4  Source Data and Documents  ....................................................................................... 36 
11.5  Archiving  ...................................................................................................................... 36 
12 Monitoring Plan  ........................................................................................ 36 
12.1  Confidentiality and Data Protection  ............................................................................ 36 
12.2  Storage of Images and Associated Health Data ........................................................... 37 
13 Research Agreements  ................................................................................ 37 
13.1  Clinical Study Report and Publication Policy  ............................................................... 37 
Appendix A – Study Site and Investigator List  ................................................... 39 
References  ........................................................................................................ 40 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 5 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
 
List of Figures  
Fig.1    ..……………………………………………………… .18 
Fig.2    ..………………………………………………………………… .20  
Fig.3  ....………………………………………………………………………………… .22 
  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 7 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
LIST OF ABBREVIATIONS AND TERMS  
AE Adverse Event  
ADE Adverse Device Effect  
AFAP  As far As Possible  
ASADE  Anticipated Serious Adverse Device Effects  
BMI Body Mass Index  
CIP Clinical Investigation Plan  
CFR Code of Federal Regulations  
COHb  Carboxyhemoglobin  
ECG Electrocardiogram  
eCRFs  Electronic Case Report Forms  
EtCO 2 End-tidal carbon dioxide  
FDA Food and Drug Administration  
GCP Good Clinical Practice (see ISO [ZIP_CODE]:2020)  
GEHC   GE HealthCare  
IRB Investigational  Review Board  
ISO International Organization for Standardization  
ITA Individual Topology Angle  
MST  Monk Skin Tone  
PI [INVESTIGATOR_548051] 2 Arterial oxygen saturation  
SpO 2 Oxygen saturation as measured by [CONTACT_548070]: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 9 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
Procedures/  
Methods:  Procedures/Methods according to ISO [ZIP_CODE] -2-61:2017 annex EE.3 (PROCEDURE for non -invasive 
laboratory testing on healthy adult volunteers) and FDA pulse  oximetry guidance (Pulse Oximeters - 
Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug 
Administration Staff, March 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
  
 
   
  
   
  
 
    
  
 
 
 
  
9.    

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 10 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
10.  
 
 
 
 
 
 
 
   
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing Part 1, Non -
invasive Development Test for the New LED Platform  
Study Number:  2023- 061-MS- GES  
 
Page 12 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
Eligibility Criteria:  Inclusion criteria:  
Participants who meet the following 
criteria will be included:  
1. Participant is adult 18- [ADDRESS_717403] be 
willing and able to comply with 
study procedures and duration.  
 Exclusion criteria:  
Participants who meet any of the following criteria will be 
excluded  from the study : 
1. Participant is considered as being morbidly obese 
(defined as BMI >39.5)  
2. Compromised circulation (i.e., Raynaud’s Syndrome), injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. ( Note: 
Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized ).  
3. Tattoo in the optical path which would limit the ability to 
test sites needed for the study.   
4. Females who are pregnant - confirmed by [CONTACT_6270] -performed 
and self -reported positive urine pregnancy test 
performed on the day of the study unless the participant 
is known to be not of child -bearing potential  
5. Participants who have smoked in the last [ADDRESS_717404] 48 hours, 
with COHb levels >3% as assessed per site standard 
operation procedure.  
6. Participants with self -reported respi[INVESTIGATOR_548052]:  
o uncontrolled / severe asthma,  
o flu,  
o pneumonia / bronchitis,  
o shortness of breath / respi[INVESTIGATOR_1506],  
o unresolved respi[INVESTIGATOR_545486],  
o emphysema, COPD, lung disease  
o Recent COVID (last 2 months)  
7. Participants with self -reported heart or cardiovascular 
conditions such as:  
o have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)  
o chest pain (angina)  
o previous heart attack  
o blocked artery  
o unexplained shortness of breath 
o congestive heart failure (CHF)  
o history of stroke  
o transient ischemic attack  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing Part 1, Non -
invasive Development Test for the New LED Platform  
Study Number:  2023- 061-MS- GES  
 
Page 13 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
o carotid artery disease  
o myocardial ischemia  
o myocardial infarction  
o cardiomyopathy  
o Cardiovascular implantable active medical device 
(such as pacemaker or automatic defibrillator)  
o Heart  rhythms other than a normal sinus rhythm 
or with respi[INVESTIGATOR_25570]  
o High blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings  
8. Participants with self -reported health conditions such as:   
o diabetes,  
o uncontrolled thyroid disease,  
o kidney disease / chronic renal impairment,  
o history of seizures (except childhood febrile seizures),  
o epi[INVESTIGATOR_002],  
o history of unexplained syncope,  
o recent history of frequent migraine headaches,  
o recent symptomatic head injury (within the last 2 months),  
o Cancer requiring chemotherapy, radiation, or currently on treatment  
9. Participants with self -reported known clotting disorders  
o history of bleeding disorders or personal history of prolonged bleeding from injury 
o history of blood clots  
o hemophilia  
o current use of blood thinner: prescription or daily use of aspi[INVESTIGATOR_248]  
o Sickle Cell Trait or Disease  
10. Participants with severe contact [CONTACT_136184], latex, silicone , or other materials found in 
pulse oximetry sensors, ECG electrodes, respi[INVESTIGATOR_136174] (self-reported)  
11. Unwillingness or inability to remove colored nail polish or non -clear artificial nails from test digits  
12. Surgical hardware in pathway which would limit the ability to test sites needed for the study  
13. Other known health condition, should be considered upon disclosure in health assessment form  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 15 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
1. BACKGROUND AND JUSTIFICATION  
 
 
    
 
 
 
 
  
 
 
 
 
 
 
 
   
Here we w i
ll collect SpO2 data with simultaneous transfer standard SpO2  
 Transfer standard is a validated pulse oximetry equipment with a calibration directly traceable to CO -oximetry. 
Test method and  protocol is developed according to ISO [ZIP_CODE]-2- 61:2017 annex EE.3 (PROCEDURE for non -invasive 
laboratory testing on healthy adult volunteers).  
Funding for this study will be provided by [CONTACT_548071] (GEHC) . 
2. DEVICE/PRODUCT DESCRIPTION  
2.1 Identity, Mechanism, and Function  
Name :  [CONTACT_548083] /Type : Life Care Solutions (LCS) – Monitoring Solutions  
Manufacturer:  GE HealthCare (GEHC)  
Software version:       Portrait Mobile Patient monitor (Hub):  
     Sensor Battery:    
      SpO2 Sensor:  
Regulatory Status :  Pre-market   
 
The investigational devices will be exclusively used for research purposes and labeled in compliance with local regulations.  
2.[ADDRESS_717405] SpO2  
 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 16 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
2.3 Packaging and Labeling  
Research conducted for this study will utilize investigational devices and devices cleared through the 510k regulatory 
process.  
 
 
 
 
 
 
The Instructions for Use (IFUs) are provided as separate documents from this protocol.  
2.4 Concomitant/Ancillary Administrations  
2.4.1 Medications and Biologic Products  
Medical grade oxygen and nitrogen are used in this study  
2.4.2 Laboratory Tests  and Sample Processing  
 No sample 
pr
ocessing is  planned as part of  the study procedures . 
2.5 Accountability  
Accurate and adequate records will be maintained  for all devices,  from time of shipment to the sites until return or 
disposal  of all devices issue d by [CONTACT_73694], as required by [CONTACT_1289] s and regulation s. The 
Principal Investigator [INVESTIGATOR_548053]/products at the investigational  
site during the study.  
2.5.1 Issuance  
The devices will be provided by [CONTACT_1034], GEHC and administered by [CONTACT_548072] . User training is provided before device administration.  
2.5.2 Disposition  
The devices will be dispositioned after the study by [CONTACT_548073], per applicable safety instruction, laws, and 
regulations. Unused investigational single -use accessories provided to the site during the study shall be returned to the 
Sponsor, GEHC. Used single -use medical devices/accessories, e.g., electrodes shall be disposed according to the 
hospi[INVESTIGATOR_307]/investigational site policy.  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 17 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
2.6 Anticipated Risks and Benefits  
The device/product  under study has undergone risk assessment, per International Standards Organization (ISO) [ZIP_CODE], 
and risks have been mitigated to levels as far as possible (AFAP).  
 
 
 
 
 
  
The risks of investigational units have been analyzed. The risks will be mitigated by [CONTACT_548074]. Labeling mitigations are included in the investigational device 
Instructions for Us e (IFU) and/or operating manuals, which will be provided to the site.  
The risks of study participation are not expected to be greater than those of similar procedures as described in ISO [ZIP_CODE]-2-61:[ADDRESS_717406] methods routinely conducted in earlier testing. There are no expected risks to 
participants, operators, or others in this study beyond those of routine/similar devices/products in clinical care  post-study 
care or follow -up is not  required by [CONTACT_15365].    
The risks of study participation are not expected to be greater than those of similar patient monitoring procedures routinely conducted in clinical practice.   
Participant s are not  expected to benefit directly from study participation . The results may benefit future patients by 
[CONTACT_4205][INVESTIGATOR_548054].    
2.6.1 Risk Category and Rationale  
Under the [LOCATION_002] Food and Drug Administration (USFDA) Guidance Document on Pulse Oximeters for Premarket Notification Submissions [510(k)], USFDA “believes pulse oximeters addressed by [CONTACT_548075]-
significant risk devices; therefor e, the study would be participant to the abbreviated requirements of 21 CFR 812.2(b).” 
Hence, it can be stated that the  sensors and 
components, as used in this study, are not consider ed a significant risk device, per the USFDA 21 CFR §812.3(m) 
definition:  
1) it is not intended as an implant;  
2) is not purported or represented to be for a use in supporting or sustaining human life;  
3) is not for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health;  
4) and it does not otherwise present a potential for serious risk to the health, safety, or welfare of a participant . 
The application of risk management analysis to the investigational units conforms to EN ISO [ZIP_CODE]: 2007. For continued 
safe use of the investigational units, the instructions for use shall be followed.  
2.6.2 Device/Product Classification and Rationale  
 LED platform is  intended for use  in the measurement of oxygen saturation (SpO 2) by [CONTACT_105]- invasive pulse 
oximetry. The FDA has classified such devices as Class II.  
 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
 
Study Number:  2023- 061-MS- GES  
 
Page 19 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
The study will be considered complete when the last visit of the final participant  is completed.  
The maximum duration of participant  participation is approximately 1 hour (typi[INVESTIGATOR_548055] <1 hour)  from the 
application of the sensors to the participant . 
This study is not intended to support a comparative claim, such as superiority or non- inferiority, so no control group is 
necessary.  
4.2 Study Population  
Participant  Population: Non-smoking, male, and female adults of varying skin tones, ages 18 to 50 years . 
Site information :  
4.3 Number of Participant s 
The study includes a minimum of 30 participant s 
 
 
 
 
 
 
 
 
4.4 Eligibility Criteria   
4.4.1 Inclusion Criteria  
Participants who meet the following criteria will be included:  
1. Participant is adult 18- [ADDRESS_717407] be willing and able to comply with study procedures and duration. 
4.4.2 Exclusion Criteria  
Participants who meet any of the following criteria will be excluded  from the study : 
1. Participant is considered as being morbidly obese (defined as BMI >39.5)  
2. Compromised circulation (i.e., Raynaud’s Syndrome), injury, or physical malformation of fingers, toes, hands, ears 
or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study.  Note: 
Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized.  
3. Tattoo in the optical path which would limit the ability to test sites needed for the study.   
4. Females who are pregnant  - confirmed by [CONTACT_6270] -performed and self- reported positive urine pregnancy test  
performed on the day of the study unless the participant is known to be not of child- bearing potential  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 20 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
5. Participants who have smoked in the last [ADDRESS_717408] 48 hours, with 
COHb levels >3% as assessed per site standard operation procedure . 
6. Participants with self -reported respi[INVESTIGATOR_136172]:  
o uncontrolled / severe asthma,  
o flu,  
o pneumonia / bronchitis,  
o shortness of breath / respi[INVESTIGATOR_1506],  
o unresolved respi[INVESTIGATOR_545486],  
o emphysema, COPD, lung disease  
o Recent COVID (last 2 months)  
7. Participants with self -reported heart or cardiovascular conditions such as:  
o have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA)  
o chest pain (angina)  
o previous heart attack  
o blocked artery  
o unexplained shortness of breath 
o congestive heart failure (CHF)  
o history of stroke  
o transient ischemic attack  
o carotid artery disease  
o myocardial ischemia  
o myocardial infarction  
o cardiomyopathy  
o Cardiovascular implantable active medical device ( such as pacemaker or automatic defibrillator ) 
o Heart  rhythms other than a normal sinus rhythm or with respi[INVESTIGATOR_25570]  
o High blood pressure: systolic >140 mmHg or diastolic >90 mmHg on 3 consecutive readings  
8. Participants with s elf-reported health conditions such as:  
o diabetes,  
o uncontrolled thyroid disease,  
o kidney disease / chronic renal impairment,  
o history of seizures (except childhood febrile seizures),  
o epi[INVESTIGATOR_002],  
o history of unexplained syncope,  
o recent history of frequent migraine headaches,  
o recent symptomatic head injury (within the last 2 months),  
o Cancer requiring chemotherapy, radiation, or currently on treatment  
9. Participants with self -reported known clotting disorders  
o history of bleeding disorders or personal history of prolonged bleeding from injury 
o history of blood clots  
o hemophilia  
o current use of blood thinner: prescription or daily use of aspi[INVESTIGATOR_248] 
o Sickle Cell Trait or Disease  
10. Participants with severe contact [CONTACT_136184], latex, silicone , or other materials found in pulse 
oximetry sensors, ECG electrodes, respi[INVESTIGATOR_136174] (self- reported)  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 24 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
5.2.1 Control Oximetry System  
The Control Pulse Oximeter, an FDA cleared device, is used to monitor the oxygen saturation levels real time throughout 
the study for participant safety and to target stable plateaus. This device is used to assess the stability of the data.  
•  
  
 
  
5.2.2 Safety Equipment   
Multi -parameter monitor used during the study to observe a participant’s vital signs including ECG tracing, heart rate, 
respi[INVESTIGATOR_697], end -tidal CO2 with capnograph, secondary monitor for the oxygen concentration being delivered to the 
participant. This  device will also serve as the pulse rate reference.  
•  
  
  
5.2.[ADDRESS_717409] / Control Oximetry System  
 The Transfer Standards have been previously compared to Arterial blood draws as measured by [INVESTIGATOR_609] -Oximetry.  
•  
  
5.3 Participant  Preparation   
Study staff will confirm that the participant  is eligible and complies with applicable site requirements prior to starting 
study procedures.  No preparation beyond that required by [CONTACT_548076].  
5.4 Description of Study  Procedures  
1. Perform health assessment and same day health screening . Take the participant’s blood pressure and record 
values.  
2. Once participant  has met all inclusion criteria, written informed consent shall be performed by a member of the 
study team.   Each participant will be given a signed copy of the consent form prior to release.   

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing
 
Study Number:  2023- 061-MS- GES  
 
Page 27 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
Any data, including images, collected for the participant , up until the time of withdrawal or discontinuation, may still be 
included in the study results and provided to the Sponsor, unless the participant  requests that their data not be used. The 
site shall document all requests by [CONTACT_3445] s regarding their data use .    
[ADDRESS_717410].  
 
  
  
  
   
6.1 Primary Assessment  
During the study period, the following participant  information shall be collected if available:  
1) Demographics to include age , biological sex race , and ethnicity.  
2) Vitals to include height (cm), weight (kg/g) , BMI, blood pressure, SpO2 readings . 
3) Skin tone  assessed from  with a Monk Skin Tone  Scale.   
4)  
5)   
6) Location of sensors  
7) Date and time of study procedures  
8) Test set -up information  
6.[ADDRESS_717411] of the investigation shall be qualified by [CONTACT_8640], training and/or experience to perform their tasks, and this shall be documented appropriately, per ISO [ZIP_CODE] :2020 for clinical 
studies . Study staff and the PI’s qualification for the study will be verified by [CONTACT_548077]’s and GCP certifications. 
Study staff and the PI [INVESTIGATOR_548056]. All the training  will be recorded on  training logs. If study staff or PI [INVESTIGATOR_548057], the Sponsor will work 
with the site to requalify the respective role or ensure the duties are reassigned appropriately by [CONTACT_779]. The Sponsor 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 28 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
reserves the right to disqualify PI [INVESTIGATOR_548058], such as repeated issues that impact participant  safety and 
data integrity.   
7.2 Training Plan for the Protocol and Research Device/Product  
The Sponsor will provide training for all participants involved in the study. This includes any individual that will operate 
any equipment involved in the study, collect any data that is a part of the study, analyze any data associated with the study, or is in any other way involved with the study. Training to the site personnel will be conducted prior to the first subject enrolled.  
The following training information will be collected in the training log prior to study enrollment:  
• Title of Training  
• Training objectives  
• Training logistics (who conducts training and training method)  
• Target audience (who will be trained)  
• Training content (including device operation, protocol review, ICF, other documentation needed)  
 
Study staff directly operating or maintaining the research device or product will be trained based on the training plan and 
qualified based on experience, and the hospi[INVESTIGATOR_307]/clinical site policy. 
The PI [INVESTIGATOR_548059]/product use in this study 
by [CONTACT_146814].  
8 SAFETY  
8.1 Anticipated Adverse Events  
Being in this study involves some foreseeable risks .  
There is always a chance of unexpected risks. Throughout the study, the Sponsor will evaluate and update safety information in study documents. In case of unexpected risks appearing, F DA will be informed by [CONTACT_1034].  
Participant s will be closely monitored by [CONTACT_464], and testing will be discontinued if more than minor discomfort or any 
signs or symptoms that could indicate medically important adverse effects related to testing are observed.  
8.2 Safety/Anticipated AE Risks  
Laboratory Testing  
The risk determination is based on the use of the device in an investigation in addition to the device itself. Generally, the  
FDA believes pulse oximeters as addressed in the FDA Guidance Document for Pulse Oximeters7 are non -significant risk 
devices. Further, the recommendation is to conduct the study in accordance with Clause [IP_ADDRESS].2 and Annex EE.2 
of ISO [ZIP_CODE]-2- 61:2017, where Annex EE.2 describes the procedure for invasive laboratory testing on healthy volunteers.  
Controlled Desaturation Study  
Desaturation of the participant  involves the administration of oxygen/nitrogen mixtures that are less than that of normal 
air, i.e., less than 21% oxygen.  
 
 
During the test, the participant  is 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
 
Study Number:  2023- 061-MS- GES  
 
Page 29 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
closely monitored and constant communication regarding the participant ’s comfort and sense of well -being is assessed. 
The ECG, pulse oximetry saturation, oxygen saturation levels , and EtCO2 are monitored. Since [ADDRESS_717412] performed 
these types of tests in this and other laboratories where we conducted approximately 8,900 desaturation tests with no 
significant negative events.  
The mask allows gas for maximum delivery. The mask is made of soft flexible plastic so as to minimize the discomfort level as much as is reasonably possible. Materials may cause some skin irritations.  
Pulse Oximetry Sensor  
Pulse Oximetry Sensor placement involves positioning pulse oximetry sensors on the volunteer participant  in the same 
manner that is used on hospi[INVESTIGATOR_9643].  The sensors may be warm to the touch. Under normal operating conditions, (no fault conditions), the sensors are not expected to overheat. If the sensors are too warm, they will be removed immediat ely.  If the sensors are too uncomfortable, they will be removed immediately.  Adhesive sensors or tape may 
cause some irritations to the skin in some p articipant s. Every effort will be made to minimize products with natural rubber 
or latex. Products containing natural rubber or latex will be identified.  The risk in the use of pulse oximetry sensors is believed to be minimal.  
ECG Electrodes  
Materials (such as the adhesive and/or gel contact) used in the electrodes may cause some skin irritations in some participant s. Typi[INVESTIGATOR_548060]. 
Because the adhesive is aggressive on the ECG pads, it may cause pulling of the skin or hair upon removal. 
Biocompatibility testing for surfa ce contact [CONTACT_164283] a requirement of the International Standards Organization (ISO) 
[ZIP_CODE] – Biological Evaluation of Medical Devices. The risk in the use of ECG electrodes is believed to be minimal.  
 
Blood Pressure Cuff  
The reported risks associated with NIBP include A) slight discomfort upon inflation of the cuff, B) possible bruising, C) 
petechial rash, and D) discoloration of the skin beneath the cuff. In rare instances the reported risks associated with NIBP 
include A) peripheral nerve injuries, B) skin tear, and C) compartment syndrome (swelling of muscles in the limb causing 
the reduction of the blood supply to the muscle).  Through literature searches of other studies, we found the 
complications of taking repeated blood pressures were temporary and involved either bruising/rash; for example, 
petechiae rash (less than 2.2%), skin redness/lines (0.8%), or tingling/discoloration in the extremity wearing the cuff while  
the cuff is inflated (0.1%).   
It is possible that the test participant  may experience an allergic reaction to the material in the cuff.   
 
Heating Pad / Hot Water Bottles  
A heating pad or hot water bottles may be used Mild discomfort 
can be expected if it is too warm. To minimize the discomfort, the participant  will be asked about comfort level. If the 
heating is too warm, it will be turned on the lowest level possible, removed or additional separation will be used between 
the heater and the site for comfort.  
8.[ADDRESS_717413], and their classifications are provided below (ISO [ZIP_CODE], 21 CFR 812.3).  
 
Adverse Device Effect (ADE):  Adverse event related to the use of an investigational medical device resulting from 
insufficiencies or inadequacies in the instructions for use, the deployment, installation, the operation, or any malfunction of the investigational medical device or from  error use.  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 30 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
 
Adverse Event (AE): Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs 
(including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device or investigational procedure.   
 
Anticipated Serious Adverse Device Effects (ASADE):  ASADE is an effect which by [CONTACT_5942], incidence, severity or 
outcome has been identified in the risk analysis report.   
 
Mild:  a mild adverse event is one in which the participant is aware of the event, but it is easily tolerated without 
intervention.   
 Moderate:  a moderate adverse event is one that causes sufficient discomfort to interfere with usual activities.  
  
Serious Adverse Device Effect (SADE): adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event . 
  Serious Adverse Event (SAE):  a serious adverse event is an adverse event that results in death, inpatient 
hospi[INVESTIGATOR_059], severe or permanent disability, a life -threatening illness or injury, fetal distress, fetal death, a 
congenital abnormality, a birth defect, or medical or surgical intervention to prevent permanent impairment to body or structure.   
 
Severe:  a severe adverse event is one that results in the inability to perform usual activities.   
 Unanticipated serious adverse device effect ([LOCATION_003]DE):  a serious adverse device effect, which by [CONTACT_5942], incidence, 
severity, or outcome has not been identified in the current version of the risk analysis report [ISO [ZIP_CODE]:2011 3.42]. In the [LOCATION_002], any serious adverse effect on health or safety or  any life -threatening problem or death caused 
by, or associated with, a device, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the study doc uments, will be reported in accordance with 21 CFR §812.3 and applicable laws 
and regulations.  
8.4 Documentation of Adverse Events  
All adverse events (AE) , including all serious adverse events (SAE) , are required to be collected, investigated , and 
documented . AEs will be collected from [describe the reporting period, e.g., from the time they enter the scan room to 
the time they leave the scan room]. All AEs will be followed through to their resolution. Documentation will include:  
• Description of Event  
• Date of onset  
• Date of resolution unless resolution does not occur during study reporting period. In the instance that resolution 
does not occur, the status of the AE will be documented (not resolved/recovered or resolving/recovering)  
• Severity (mild, moderate, or severe)  
 Mild : Symptom(s) barely noticeable to the participant  or does not make the participant  uncomfortable. 
The AE does not influence performance or functioning. Prescription drugs are not ordinarily needed for 
relief of symptom(s).  
 Moderate: Symptom(s) of sufficient  severity to make the participant  uncomfortable. Performance of 
daily activities is influenced. Treatment of symptom(s) may be needed.  
 Severe: Symptom(s) of a sufficient severity to cause the participant  severe discomfort. Treatment for 
symptom(s) may be given.  
• Serious (yes/no)  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
 
Study Number:  2023- 061-MS- GES  
 
Page 31 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
• Causal relationship to investigational or comparator medical device? (not related, possible, probable, or causal 
relationship) 
 Not related: Relationship to the device, comparator or procedures can be excluded when:  
• the event has no temporal relationship with the use of the investigational device, or the procedures related to application of the investigational device;  
• the serious adverse event does not follow a known response pattern to the medical device (if the response pattern is previously known) and is biologically implausible;  
• the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasible - and reintroduction of its use (or increase of the 
level of activation/exposure), do not impact on the serious adverse event;   
• the event involves a body -site or an organ that cannot be affected by [CONTACT_41491];  
• the serious adverse event can be attributed to another cause (e.g., an underlying or concurrent 
illness/clinical condition, an effect of another device, drug, treatment or other risk factors);  
• the event does not depend on a false result given by [CONTACT_5749], when applicable;  
In order to establish the non- relatedness, not all the criteria listed above might be met at the same 
time, depending on the type of device/procedures and the serious adverse event.  
 Possible :  The relationship with the use of the investigational device or comparator, or the relationship 
with procedures, is weak but cannot be ruled out completely. Alternative causes are also possible (e.g., an underlying or concurrent illness/ clinical conditi on or/and an effect of another device, drug or 
treatment). Cases where relatedness cannot be assessed, or no information has been obtained should 
also be classified as possible.  
 Probable:  The relationship with the use of the investigational device or comparator, or the relationship with procedures, seems relevant and/or the event cannot be reasonably explained by [CONTACT_5748].  
 Causal relationship:  the serious adverse event is associated with the investigational device, comparator or with procedures beyond reasonable doubt when:  
• the event is a known side effect of the product category the device belongs to or of similar devices and procedures;  
• the event has a temporal relationship with investigational device use/application or procedures;  
• the event involves a body -site or organ that  
 the investigational device or procedures are applied to;  
 the investigational device or procedures have an effect on;  
• the serious adverse event follows a known response pattern to the medical device (if the response pattern is previously known);  
• the discontinuation of medical device application (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of 
activation/exposure), impact on the serious adverse event (when clinically feasible);  
• other possible causes (e.g., an underlying or concurrent illness/clinical condition or/and an 
effect of another device, drug or treatment) have been adequately ruled out;  
• harm to the participant  is due to error in use;  
• the event depends on a false result given by [CONTACT_75698], when 
applicable;  
In order to establish the relatedness, not all the criteria listed above might be met at the same time, depending on the type of device/procedures and the serious adverse event.  
• Causal relationship to investigational procedure? (not related, possibly related, probably related, or causal 
relationship) 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 32 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
• Treatment given and/or action taken (procedure stopped, withdrawn from study, or no action)  
• Anticipated (yes/no)  
• Signals from AE that might indicate a serious health threat.  
8.5 Reporting of Safety Events  
The following events are to be reported to the Sponsor within 72 hours of the event occurrence and to the EC per their 
policy:  
• All SAEs and U SADEs  
• All device issues that could possibl y lead to an SAE  
• Any signal from an AE that might indicate a serious health threat  
• Unanticipated AE and unanticipated ADEs  
Additional follow -up information may be requested by [CONTACT_1034].  In addition, safety information  may be shared with  
regulatory agencies  and other participating sites , as required by [CONTACT_73702].  
The Sponsor contact [CONTACT_246340] :    
Research Program Integrator (see Appendix  C) 
e-mail:  
8.6 Reporting of Device Deficiencies/Complaints  
Device deficiency:  an inadequacy of a medical device with respect to its identity, quality, durability, reliability, usability, 
safety, or performance, such as malfunctions, use errors, and inadequacy in the information supplied by [CONTACT_439121].  
Device deficiencies/complaints should be reported to the study Sponsor contact [CONTACT_73703]. All device deficiencies/complaints will be collected, fully investigated, and documented in the source document 
during the study reporting period. The Principal Investigator [INVESTIGATOR_548061] a SAE . 
[ADDRESS_717414] OF THE STUDY  
The study will be carried out per  the protocol and with principles enunciated in the current version of the Declaration of 
Helsinki; the guidelines of Good Clinical Practice (GCP)  for medical devices , as set forth by [CONTACT_5891] [ZIP_CODE] and ISO [ZIP_CODE]; The 
study will be conducted in accordance with the Declaration of Helsinki , 21 CFR 50, and 21 CFR 812 for non -significant risk 
device study investigations. The study will not commence until the approval has been received from the IRB.  
The study will be conducted and reported per  applicable policies of the Ethics Committee (EC) and governing regulatory 
authorities.  
If national or regional EC requirements are less strict than the requirements of GCP, such as ISO [ZIP_CODE]:  for medical 
devices , the S ponsor shall apply the requirements of this International Standard to the greatest extent possible, 
irrespective of any lesser requirements, and shall record such efforts.  
9.1 Ethics Committee  
The responsible P rincipal Investigator at each site will ensure that approval from an appropriately constituted EC is 
attained for the clinical study prior to enrolling participant s, and the PI [INVESTIGATOR_548062].  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 33 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
The PI [INVESTIGATOR_471478] 5 working days of such occurrence. 
If approval is terminated or suspended, the Principal Investigator [INVESTIGATOR_548063] a written  
explanation.  
9.2 Regulatory Agencies and Competent Authority(ies)  
GEHC will obtain approval from the local regulatory agency or competent authority, before the start of the clinical trial, if  
necessary, per applicable local laws and regulations. Any additional requirements imposed by [CONTACT_548078], if applicable.  
9.3 Management of Protocol Modifications and Amendments  
Substantial amendments will only be implemented after approval of the EC. Non- substantial modifications may be made 
during the normal course of device optimization, maintenance, and feasibility testing. Non- substantial modifications will 
be communicated to  the competent authority (CA) as soon as possible, if applicable, and to the EC per their policy.  
9.4 Management of Protocol Deviations  
A deviation is any instance(s) of failure to follow, intentionally or unintentionally, the requirements of the protocol.  Under 
emergency circumstances, deviations from the protocol to protect the rights, safety, and wellbeing of human participant s 
may proceed without prior approval of the Sponsor and the EC/CA. Such deviations shall be documented and reported to the Sponsor and the EC/CA as soon as possible. Deviations will be reported as:  
• Critical Deviations:  Deviations that significantly affect the safety, efficacy, integrity, or conduct of the study. 
These deviations must be reported to the Sponsor no later than 5 working days from awareness of occurrence and reported to the EC per the deviation reporting po licy. 
• Non -Critical Deviations:  Protocol deviations that do not significantly affect the safety, efficacy, integrity, or 
conduct of the study. These deviations must be documented on the CRF Protocol Deviation page and will be reviewed by [CONTACT_11200].  
The Sponsor will assess and implement any corrective or preventative actions necessary, such as retraining the study staff and PI.  
9.5  Participant  Information and Informed Consent    
The investigators will explain to each participant the nature of the study, its purpose, the procedures involved, the expected duration of exposure to the investigational device, the potential risks and benefits, and any potential discomforts. Each participant will be informed that participation in the study is voluntary, that he/she may withdraw 
his/her from the study at any time, and that withdrawal of consent will not affect his/her subsequent medical assistance 
and treatment. The participant must be informed that his/her study records may be examined by [CONTACT_548079].  
All participant for the study will be provided an informed consent form (ICF), describing the study and providing sufficient 
information, to allow the participant (i) to make an informed decision about his/her participation in the study, and (ii) to 
be ful ly aware of his/her rights under the applicable law. Informed consent documents will be subject to approval by [CONTACT_548080].  
The participant should read and consider the statement before signing and dating the ICF and shall be given a copy of the signed document. The ICF must also be signed and dated by [CONTACT_093] (or his/her designee), and it shall be retained as part of the study records.  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 34 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
9.6  Suspension/ Early Termination of the Study  
Participation in the study is voluntary. The participant may choose to withdraw the participant from the study at any 
point. If a participant officially withdraws from the study, the laboratory staff will document the reason for withdrawal in 
the case report.   
   
Participation in the study may also be stopped at any time by [CONTACT_458] [INVESTIGATOR_548064]- investigators or 
sponsor.   
The Sponsor may  suspend or terminate  the study prematurely for various significant and documented reasons. Reasons 
for suspension or termination may include but are not limited to insufficient participant  recruitment, updated risk profile 
impacting participant  safety, alterations in accepted clinical practice impacting study procedures, early evidence of 
benefit or harm of the research product, or serious or repeated deviations by [CONTACT_093].  
Suspension or termination can occur at individual sites or across the study, as applicable. The decision to suspend or 
terminate the study should be shared in writing with all parties described above.  
If the reason for study suspension is resolved, the deciding party shall inform all appropriate parties of the decision and 
actions to resume study procedures.   
 
All the data collected prior to study suspension or early termination will be stored and can be  used by [CONTACT_1034].   
 Withdrawal of IRB approval shall be reported to the sponsor by [CONTACT_19452] 2 working days.  
 
 
In case of early termination of the study, all study participants should be followed until the resolution of any pending 
adverse event(s).   
 
10 STATISTICAL  METHODS  
10.1 Statistical Hypothesis 
No statistical hypothesis is being tested in this study. 
10.2 Sample Size Determination  
Per ISO [ZIP_CODE]-2- 61:2017, at least [ADDRESS_717415], with 
SaO 2 values distributed on several saturation plateaus spanning the range of 70 -100%.   
10.3 Statistical Analysis  
Data collected will be analyzed by [CONTACT_548081].  
10.3.1   General Statistical Methods  
Data analysis will follow ISO  [ZIP_CODE]-2- 61, 2017 , and the FDA Guidance Document for Pulse Oximeters (FDA Guidance, 
March 4, 2013). The reference guidance documents clearly define the study, number of subjects, data points needed for the analysis and handling of missing data or data that is removed from the analysis. This is achieved through a minimum 
of [ADDRESS_717416] and Reference values equally distributed over the specified SpO
2 accuracy range (70-
100%) of the device under test. The data will be collected on a minimum of 10 healthy adult volunteer subjects who range 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
 
Study Number:  2023- 061-MS- GES  
 
Page 35 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
in age, gender and skin tone. The controls of the study will be provided in the following manner. A control oximeter will 
be used to assess the stability of the plateaus for data collection . 
10.3.2   Analysis of Primary Endpoint(s)  
Data analysis will follow ISO80601-2- 61, 2017 and the FDA Guidance Document  for Pulse Oximeters (FDA Guidance, 
March 4, 2013).[ADDRESS_717417] if 
possible.     
10.5 Deviation(s) from the Original Statistical Plan  
Any changes or deviations from the original statistical plan specified in this protocol will be described and justified in th e 
study final report per ISO [ZIP_CODE]:2020.   
11 QUALITY ASSURANCE AND CONTROL  
11.1 Data Management  
Data management processes for handling study data will be maintained by [CONTACT_1034].  
11.2 Completion of Case Report Forms (CRFs)  
The data reported on the eCRFs shall be derived from source documents and be consistent with these source documents. Electronic CRFs (eCRFs ) will be used to collect data . The Sponsor will provide eCRFs and train study staff on completion of 
eCRFs using Good Documentation Practices (GDP). eCRF Completion Guidelines (CCG) may be provided by [CONTACT_73710].  
eCRFs are to be completed as information becomes available at the site. e CRFs should be signed by [CONTACT_73711], in 
indicated area(s), to certify the contents of the form. The PI [INVESTIGATOR_548065].  
If any discrepancies are discovered on the eCRF, whether during monitoring or during data review by [CONTACT_3476], a query will be raised, and the site shall make the correction within the electronic database, noting the reason for change. Data will be co nsidered clean once all queries are answered and closed.   
 
If the Sponsor discovers discrepancies on eCRFs, a query will be raised, and necessary corrections will be made by [CONTACT_779]. The reason for any changes will be noted. All queries will be resolved prior to study completion.  
 
11.[ADDRESS_717418] Keepi[INVESTIGATOR_73682] a manner  that assures control and traceability.  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 36 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
 Only authorized users, as determined by [CONTACT_246337], 
are
 allowed to login and view data in Medidata. Access is controlled through study level, role -based security.  
 
 
 
 
11.[ADDRESS_717419] be retained throughout the investigation, 
including printed or electronic documents containing source data. Elements should include:  
• Source data and documentation relevant to data recorded for participant  screening and eCRF corroboration.  
Questionnaires may be directly entered into the eCRF and therefore considered source . 
• Participant  records  containing the completed ICFs and (e)CRFs . 
• Regulatory binder containing the protocol and any subsequent amendments, EC submissions and approvals, 
blank ICF(s), and site logs . 
• Reference manuals  containing investigator responsibilities, Sponsor, AE/SAE and informed consent guidelines, 
applicable study aids and training materials, and operator’s manuals . 
The PI [INVESTIGATOR_471480], 
audits, EC review, and regulatory authority inspections . 
11.[ADDRESS_717420] be archived for a minimum of  ten (10)  years after study termination or premature termination of the 
clinical study .  
12 MONITORING PLAN  
In collaboration with the site, the Sponsor will ensure proper monitoring of the study to confirm that all the research  
requirements are met. Monitoring visits will oversee the progress of a clinical investigation and ensure that it is 
conducted, recorded, and reported per  the protocol, written procedures, Good Clinical Practice (GCP) ISO [ZIP_CODE]:2020, 
and the applicable regulatory requirements.  
12.1 Confidentiality and Data Protection  
The investigator affirms and upholds the principle of the participant 's right to privacy, and the investigator shall comply 
with applicable privacy laws. Especially, data privacy will be ensured when presenting the data at scientific meetings or publishing data in scientific journals.  
Individual participant  medical information obtained because of this study will be considered confidential, and disclosure 
to third parties will be prohibited. Participant  confidentiality will be further ensured by [CONTACT_548082]. For data verification purposes, authorized representatives of the Sponsor, a competent authority ( CA), or 
an ethics committee (EC) may require direct access to parts of the medical records relevant to the study, including 
participant  medical histo ry. 
A checklist will be maintained identifying the contents of the Trial Master File / Project folder  
 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 37 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
 
The participant’s name [CONTACT_548084], Health Assessment Form, and a participant 
participation list. The data collection form will only use a participant number for the day of the test along with participant demographics. A name [CONTACT_164305].   
 
 
Records identifying the participant’s name [CONTACT_7637] a secured location with either a locked file or locked door.   Access to these files will be on a limited basis. Potential reviewers of this information include: Element 
representatives collecting t he information and conducting the study, Medical Director for Element, Regulatory 
Authorities, Department of Health and Human Services (DHHS) agencies, Governmental agencies in other countries, Salus Independent Review Board and representatives of the Sponsor. This group may use the information to conduct independent audits and reviews to verify compliance of the regulatory requirements for these studies but not copy the 
information.   
 
 
Data files stored electronically will be associated with a participant based off of participant #, date and by [CONTACT_348562]. The original device electronic data files will be preserved in its original form.     
 
Data files, data collection records with participant demographics and participant number may be additionally copi[INVESTIGATOR_530], (after de -identification, if applicable) reviewed and supplied to the commercial sponsor for the study or Contractors 
associated with Element for data analysis purposes.  
 
 
All study records will be stored for at least [ADDRESS_717421] of the clinical investigation and results wi ll be entered upon completion.  
This study may not qualify as an Applicable Clinical Trial (ACT) and information about this trial may not be made publicly available. However, the sponsor may voluntarily register the clinical trial and submit summary results information to the databank. I f so, it’s possible the results may not be published until after a product is cleared or approved by [CONTACT_1622]. The 
conditions of publication are described in a separate contractual agreement . 
 

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 38 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
  

Study Title: Wireless Disposable SpO2 Sensor Hypoxia Testing 
  
Study Number:  2023- 061-MS- GES  
 
Page 40 of 40  
 Version 2.0; 08JAN2024  
Property of GE HealthCare – C onfidential  
REFERENCES  
      
1. Fouzas S, Priftis KN, Anthracopoulos MB. Pulse oximetry in pediatric practice. Pediatrics . Oct 
2011;128(4):740- 52. doi:10.1542/peds.2011 -0271 
2. Batchelder PB, Raley DM. Maximizing the laboratory setting for testing devices and understanding 
statistical output in pulse oximetry. Anesth Analg. Dec 2007;105([ADDRESS_717422]):S85-S94. 
doi:10.1213/01.ane.[PHONE_11418].[ZIP_CODE].ab  
3. Gehring H, Duembgen L, Peterlein M, Hagelberg S, Dibbelt L. Hemoximetry as the "gold standard"? 
Error assessment based on differences among identical blood gas analyzer devices of five manufacturers. 
Anesth Analg. Dec 2007;105([ADDRESS_717423]):S24 -S30. doi:10.1213/01.ane.[PHONE_11419].[ZIP_CODE].cc  
4. Tin W, Lal M. Principles of pulse oximetry and its clinical application in neonatal medicine. Semin Fetal 
Neonatal Med. Jun 2015;20(3):192 -7. doi:10.1016/j.siny.2015.01.[ADDRESS_717424] of Skin Pi[INVESTIGATOR_548066]. J Pediatr . Mar 2017;182:375 -377 e2. doi:10.1016/j.jpeds.2016.11.043  
7. FDA -- U.S. Food and Drug Administration. Pulse Oximeters -- Premarket Notification Submissions 
[510(k)s] - Guidance for Industry and Food and Drug Administration Staff. March 4, 2013. 
https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm0813
52.pdf . Accessed December 02, 2019 .  
8. FDA -- U.S. Food and Drug Administration. Pulse Oximeters -- Premarket Notification Submissions 
[510(k)s] - Guidance for Industry and Food and Drug Administration Staff . 2013. Accessed March 4. 
https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm0813
52.pdf  
 
End of Document  
 
